NDARECTALSUPPOSITORY
Approved
Sep 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMETE-CON (benzquinamide hydrochloride) is a rectal suppository indicated for the prevention and treatment of nausea and vomiting. It is a small-molecule antiemetic agent administered via rectal route, offering an alternative delivery method for patients unable to tolerate oral or parenteral formulations.
LOE Approaching
This legacy product is nearing loss of exclusivity with minimal current pipeline activity, suggesting limited growth opportunities and a shrinking brand team focused on defending market share.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on EMETE-CON offers limited career growth given its approaching loss of exclusivity and minimal linked job openings. This role is better suited for experienced professionals managing legacy products or those seeking stable, established therapeutic area experience rather than career advancement.
Brand ManagerField Sales Representative
Worked on EMETE-CON at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.